首页 › 急性髓系白血病 › 北卡罗来纳州 › Durham
Durham NC 急性髓系白血病临床试验
33项针对 急性髓系白血病的研究正在 Durham及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
招募中2 期
- Duke University Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 距离 10 英里
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
招募中观察性研究欢迎健康志愿者
- Durham VA Medical Center, Durham
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
招募中2 期
- Duke University Medical Center, Durham
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
招募中2 期
- Duke University Medical Center, Durham
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
招募中2 期
- Duke University Medical Center, Durham
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
招募中2 期
- Duke University Medical Center, Durham
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
招募中3 期
- Duke University Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 距离 10 英里
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
招募中1/2 期
- Duke University Medical Center, Durham
Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
招募中1 期
- University of North Carolina at Chapel Hill, Chapel Hill · 距离 10 英里
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
招募中1/2 期
- UNC School of Medicine, Division of Hematology, Chapel Hill · 距离 10 英里
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
招募中3 期
- US-Chapel Hill-UNCNORTHCAROLINA, Chapel Hill · 距离 10 英里
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
招募中1/2 期
- Duke University Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 距离 10 英里
A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
招募中1 期
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 距离 10 英里
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
招募中3 期
- Duke University Medical Center, Durham
- University of North Carolina, Chapel Hill, Chapel Hill · 距离 10 英里
ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
招募中1 期
- University of North Carolina at Chapel Hill, Chapel Hill · 距离 10 英里
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
招募中1/2 期
- Research Site, Durham
- Research Site, Chapel Hill · 距离 10 英里
Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents
招募中2 期
- University of North Carolina at Chapel Hill, Chapel Hill · 距离 10 英里
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
招募中观察性研究
- Duke University Medical Center, Durham
- University of North Carolina at Chapel Hill, Chapel Hill · 距离 10 英里
A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their Caregivers
招募中
- University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill · 距离 10 英里
Registry of Older Patients With Cancer
招募中观察性研究
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 距离 10 英里
IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)
招募中2 期
- UNC Hospitals, University of North Carolina at Chapel Hill, Chapel Hill · 距离 10 英里
A Study of Revumenib and Mezigdomide in People With Leukemia
招募中1/2 期
- University of North Carolina (Data Collection Only), Chapel Hill · 距离 10 英里
SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation
招募中1 期
- UNC Hospitals, University of North Carolina at Chapel Hill, Chapel Hill · 距离 10 英里
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
招募中1 期
- University of North Carolina, Chapel Hill · 距离 10 英里
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
招募中2/3 期
- Duke University, Durham
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
招募中1/2 期
- Duke University, Durham
- UNC Hospital, Chapel Hill · 距离 10 英里
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
招募中2 期
- University of North Carolina, Chapel Hill · 距离 10 英里
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
招募中1 期
- Duke Blood Cancer Center, Durham
CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
招募中1 期
- Duke Cancer Center, Durham
Novel Digital Application for Patients With Acute Leukemia
招募中
- Duke University, Durham
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
招募中观察性研究
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 距离 10 英里
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
招募中1/2 期
- Duke University Medical Center, Durham
Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
招募中欢迎健康志愿者
- Duke University, Durham
- University of North Carolina at Chapel Hill, Chapel Hill · 距离 10 英里
其他城市的 急性髓系白血病试验
- Houston, TX85 项研究
- New York City, NY51 项研究
- Boston, MA44 项研究
- Seattle, WA41 项研究
- Baldwin Park, CA40 项研究
- Columbus, OH35 项研究
- Philadelphia, PA34 项研究
- Atlanta, GA31 项研究
- Tampa, FL29 项研究
- Chicago, IL26 项研究
- Portland, OR25 项研究
- Washington, DC24 项研究
Durham的其他研究
- 乳腺癌64 项研究
- 癌症（所有类型）58 项研究
- 非小细胞肺癌39 项研究
- 多发性骨髓瘤37 项研究
- 转移性癌症33 项研究
- 前列腺癌32 项研究
- 肺癌32 项研究
- 结直肠癌28 项研究
- 卵巢癌27 项研究
- 慢性淋巴细胞白血病27 项研究
- 心力衰竭26 项研究
- 胰腺癌24 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月6日。每项研究自行设定入选标准，由研究团队决定谁能参与。